Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas.
In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the company's second quarter results, Bayer is well on its way to making good on that goal.
It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines.
Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.
As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market.
Bayer HealthCare has scored approval for the first chewable drug approved by the agency for treating osteoarthritis in dogs, a disease that accounts for pain in about 20% of canines older than one year.
Should Bayer sell some of the consumer brands it's buying from Merck in a $14 billion deal? Analysts say a few of them--Coppertone sun products, for instance--don't quite fit with Bayer's product lineup. Buyers appear to be knocking. But Bayer says it will keep those brands, thank you very much.
Building on approvals in the U.S. and EU, Bayer Healthcare said Japan has approved Nexavar to treat patients with unresectable differentiated thyroid carcinoma.
The inevitable has happened for Bayer's fast-selling anticoagulant blockbuster, Xarelto. Someone in the U.S. has filed a lawsuit over its safety concerns. In fact, a number of lawsuits have been filed, according to reports in a German newspaper.
Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.